Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis
Objectives: The aim of this study was to determine whether convalescent blood products (CBPs) offer a survival advantage for patients with severe acute respiratory infections of viral etiology. Methods: Up-to-date trials were identified by the authors through searches of the MEDLINE, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, and medRxiv databases from inception up to September 14, 2020. Meta-analyses were performed using a random-effects model. Results: According to the observational studies, patients who received CBPs showed a decline in all-cause mortality compared with patients who did not receive CBPs (odds ratio (OR) 0.36, 95% confidence interval (CI) 0.23–0.56; p < 0.00001). However, the randomized controlled trials (RCTs) showed no difference between the intervention group and the control group regarding all-cause mortality (OR 0.82, 95% CI 0.57–1.19; p = 0.30). The use of CBPs did not increase the risk of adverse events (OR 0.88, 95% CI 0.60–1.29; p = 0.51). Using CBPs earlier compared with using CBPs later was associated with a significant reduction in all-cause mortality (OR 0.18, 95% CI 0.08–0.40; p < 0.0001). Conclusions: Based on the outcomes of RCTs, CBPs may not decrease all-cause mortality. Furthermore, compared with later initiation of CBP therapy, earlier initiation of this therapy may decrease the rate of mortality..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:102 |
|---|---|
| Enthalten in: |
International Journal of Infectious Diseases - 102(2021), Seite 397-411 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shuai Shao [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| doi: |
10.1016/j.ijid.2020.09.1443 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ013593706 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ013593706 | ||
| 003 | DE-627 | ||
| 005 | 20230310055540.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2020.09.1443 |2 doi | |
| 035 | |a (DE-627)DOAJ013593706 | ||
| 035 | |a (DE-599)DOAJ44dd7e6eb19548ac830589d71f795673 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 100 | 0 | |a Shuai Shao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of convalescent blood products for patients with severe acute respiratory infections of viral etiology: A systematic review and meta-analysis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Objectives: The aim of this study was to determine whether convalescent blood products (CBPs) offer a survival advantage for patients with severe acute respiratory infections of viral etiology. Methods: Up-to-date trials were identified by the authors through searches of the MEDLINE, Embase, Cochrane Library, Web of Science, ClinicalTrials.gov, and medRxiv databases from inception up to September 14, 2020. Meta-analyses were performed using a random-effects model. Results: According to the observational studies, patients who received CBPs showed a decline in all-cause mortality compared with patients who did not receive CBPs (odds ratio (OR) 0.36, 95% confidence interval (CI) 0.23–0.56; p < 0.00001). However, the randomized controlled trials (RCTs) showed no difference between the intervention group and the control group regarding all-cause mortality (OR 0.82, 95% CI 0.57–1.19; p = 0.30). The use of CBPs did not increase the risk of adverse events (OR 0.88, 95% CI 0.60–1.29; p = 0.51). Using CBPs earlier compared with using CBPs later was associated with a significant reduction in all-cause mortality (OR 0.18, 95% CI 0.08–0.40; p < 0.0001). Conclusions: Based on the outcomes of RCTs, CBPs may not decrease all-cause mortality. Furthermore, compared with later initiation of CBP therapy, earlier initiation of this therapy may decrease the rate of mortality. | ||
| 650 | 4 | |a Convalescent plasma | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Severe acute respiratory infections of viral etiology | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Meta-analysis | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 700 | 0 | |a Yishan Wang |e verfasserin |4 aut | |
| 700 | 0 | |a Hanyujie Kang |e verfasserin |4 aut | |
| 700 | 0 | |a Zhaohui Tong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International Journal of Infectious Diseases |d Elsevier, 2015 |g 102(2021), Seite 397-411 |w (DE-627)DOAJ000043923 |x 18783511 |7 nnns |
| 773 | 1 | 8 | |g volume:102 |g year:2021 |g pages:397-411 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijid.2020.09.1443 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/44dd7e6eb19548ac830589d71f795673 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1201971220321597 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/1201-9712 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 102 |j 2021 |h 397-411 | ||